Marker Therapeutics, Inc. (NASDAQ:MRKR) Receives Consensus Rating of “Buy” from Analysts

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have earned a consensus recommendation of “Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.1667.

Several brokerages have weighed in on MRKR. UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Wednesday, October 8th. Zacks Research upgraded Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. Wall Street Zen cut Marker Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Finally, HC Wainwright initiated coverage on Marker Therapeutics in a report on Monday, December 8th. They set a “buy” rating and a $10.00 target price on the stock.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Marker Therapeutics in the second quarter worth $33,000. Two Sigma Investments LP bought a new position in shares of Marker Therapeutics in the 3rd quarter worth about $33,000. Finally, Virtu Financial LLC bought a new position in shares of Marker Therapeutics in the 3rd quarter worth about $25,000. 22.39% of the stock is currently owned by institutional investors.

Marker Therapeutics Stock Up 3.5%

Shares of MRKR opened at $1.47 on Monday. The firm has a market cap of $24.50 million, a price-to-earnings ratio of -1.20 and a beta of 1.35. The business’s 50 day moving average is $1.09 and its two-hundred day moving average is $1.22. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $5.95.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. The business had revenue of $1.23 million during the quarter, compared to analyst estimates of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. On average, equities analysts expect that Marker Therapeutics will post -0.65 earnings per share for the current fiscal year.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.